<DOC>
	<DOC>NCT00564668</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial was to investigate the safety and efficacy of NN2000-Mix30 produced by NN2000 process compared to that of NN-X14Mix30 produced by current process in Japanese subjects with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Subjects with type 2 diabetes Subjects with insulin treatment for at least 24 weeks Current treatment with premixed biphasic human insulin preparation for at least 12 weeks HbA1c lesser than or equal to 11.0% Recurrent severe hypoglycaemia Proliferative retinopathy or maculopathy requiring acute treatment Impaired renal function Cardiac diseases Uncontrolled hypertension Subjects with known malignant tumour Total daily insulin dose greater than or equal to 100 IU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>